Method for enhancing the antibody response to specific antigens with Interleukin-10

• US 5,866,134 A
• Filed: 03/24/1995
• Issued: 02/02/1999
• Est. Priority Date: 03/24/1995
• Status: Expired due to Fees

• Current Assignee: Schering Corporation (Merck & Co., Inc.)
• Original Assignee: Schering Corporation (Merck & Co., Inc.)
• Inventors: Fine, Jay S., Grace, Michael J.
• Primary Examiner(s): Housel, James C.
• Assistant Examiner(s): PORTNER, VIRGINIA ALLEN
• Application Number:
  US08/410,199
• Time in Patent Office: 1,411 Days
• Field of Search: 424/852, 424/278.1, 424/244.1, 424/234.1
• US Class Current: 424/195.11
• CPC Class Codes: A61K 2039/55527 Interleukins
• CPC Class Codes: A61K 39/092 Streptococcus
• CPC Class Codes: A61K 39/39 characterised by the immunostimulating additives, e.g. chemical adjuvants
• CPC Class Codes: A61P 31/04 Antibacterial agents

Abstract

A method for enhancing the immune response of a mammal to a vaccine comprising administering to such a mammal an effective amount of IL-10 in conjunction with the vaccine. A pharmaceutical composition comprised of an effective amount of IL-10, a natural, synthetic or recombinant antigen and a pharmaceutcally acceptable carrier.

Claims

1. A method for enhancing an immune response of a mammal to a polysaccharide vaccine comprising administering to a mammal in need of vaccination an effective amount of Interleukin-10 (IL-10) in conjunction with the vaccine.

2. The method of claim 1 wherein the mammal is human.

3. The method of claim 1 wherein the mammal is immunocompromised.

4. The method of claim 3 wherein the mammal is immunocompromised due to age.

5. The method of claim 1 wherein the IL-10 is administered in an amount of 2-150 μ

g per kilogram of body weight.

6. The method of claim 5 wherein the IL-10 is administered in an amount of 2-80 μ

g per kilogram of body weight.

7. The method of claim 5 wherein the IL-10 is administered in an amount of 25 μ

g per kilogram of body weight.

8. The method of claim 1 wherein the IL-10 is administered 2-4 days prior to the administration of the vaccine.

9. The method of claim 1 wherein the vaccine is a pneumococcal polysaccharide vaccine.

10. A method for enhancing an immune response of a mammal to a polysaccharide vaccine wherein the mammal is immunocompromised due to age comprising:

administering to said mammal an immune-response enhancing amount of Interleukin-10 (IL-10) in conjunction with a polysaccharide vaccine.

11. The method of claim 10 wherein the IL-10 is administered in an amount of 2-150 μ

g per kilogram of body weight.

12. The method of claim 11 wherein the amount of IL-10 which is administered is 2-80 μ

g per kilogram of body weight.

13. The method of claim 10 wherein the mammal is a human.

14. The method of claim 10 wherein the IL-10 is administered 2-4 days prior to the administration of the vaccine.

15. A pharmaceutical composition comprising an immunological enhancing amount of Interleukin-10 (IL-10);

and a vaccine.

16. The pharmaceutical composition of claim 15 wherein the IL-10 is contained within a sustained release formulation.

17. A kit for enhancing an immunogenic response of a mammal to antigens in a polysaccharide vaccine comprising a container of a pharmaceutical composition of Interleukin-10 (IL-10), and a pharmaceutically acceptable carrier therefor;

and a container of a polysaccharide vaccine.

18. The kit claim 17 wherein the IL-10 is contained within a sustained release formulation.

19. The kit of claim 18 wherein the vaccine is a pneumococcal polysaccharide vaccine.